Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

New Market Study Published: Anaplastic Thyroid Cancer - Pipeline Review, H1 2013


Print article Print article
2013-03-31 15:30:20 - New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

Global Markets Direct's, 'Anaplastic Thyroid Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Anaplastic Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anaplastic Thyroid Cancer. Anaplastic Thyroid Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of

data for the indicated disease.


Full Report Details at
- www.fastmr.com/prod/556358_anaplastic_thyroid_cancer_pipeline_re ..


Scope

* A snapshot of the global therapeutic scenario for Anaplastic Thyroid Cancer.
* A review of the Anaplastic Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Anaplastic Thyroid Cancer pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Anaplastic Thyroid Cancer.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Anaplastic Thyroid Cancer pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Anaplastic Thyroid Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Anaplastic Thyroid Cancer
Anaplastic Thyroid Cancer Therapeutics under Development by Companies
Anaplastic Thyroid Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Anaplastic Thyroid Cancer Therapeutics - Products under Development by Companies
Anaplastic Thyroid Cancer Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Anaplastic Thyroid Cancer Therapeutics Development
Daiichi Sankyo Company, Ltd
Plexxikon Inc.
Exelixis, Inc.
OXiGENE, Inc.
Anaplastic Thyroid Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
efatutazone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PLX-3397 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fosbretabulin disodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fosbretabulin tromethamine + [carboplatin] + [paclitaxel] - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sunitinib malate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
efatutazone + [paclitaxel] - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bevacizumab + [doxorubicin] - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PLX-4720 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anaplastic Thyroid Cancer Therapeutics - Drug Profile Updates
Anaplastic Thyroid Cancer - Product Development Milestones
Featured News & Press Releases
Sep 17, 2012: OXiGENE Announces Agreement With FDA On Special Protocol Assessment For Phase III Trial Of Zybrestat In Anaplastic Thyroid Cancer
Sep 07, 2012: Oxigene To Present Data Showing Importance Of Local Site Pathology Confirmation In Phase II/III Clinical Trial Of Zybrestat In Anaplastic Thyroid Cancer
Sep 02, 2012: Azanta Pharma And Lavi Enter Into Agreement To Provide Zybrestat In Israel On Compassionate Use Basis
Aug 22, 2012: OXiGENE Expands ZYBRESTAT Named Patient Program With Azanta
Oct 31, 2005: FDA Grants ZD6474 (Zactima) Orphan Drug Designation For The Investigation Of Rare Forms Of Thyroid Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Anaplastic Thyroid Cancer, H1 2013
Products under Development for Anaplastic Thyroid Cancer - Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013
Number of Products under Investigation by Universities/Institutes, H1 2013

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=556358&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com